Drug Profile
Research programme: ocular therapeutics - Benitec Biopharma
Alternative Names: BB 201; BB 202; BB AMD 211; BB AMD 231; TT 211; TT 231Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Tacere Therapeutics
- Developer Benitec Biopharma
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in Australia (Intravitreous, Injection)
- 13 Oct 2016 Preclinical trials in Wet age-related macular degeneration in USA (IV), before October 2016 (Benitec Biopharma pipeline, October 2016)
- 12 Oct 2016 Benitec Biopharma plans to file an IND application with the US FDA in USA for Age-related macular degeneration in 2017 (Benitec Biopharma Pipeline, October 2016)